xin zheng

Prof. Dr. xin zheng

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Heart
Verified
Journal Article
Open access
PDF file
JSJiali Song
Jiali Song
KMKarthik Murugiah
Karthik Murugiah
SHShuang Hu
Shuang Hu
YGYan Gao
Yan Gao
XLXi Li
Xi Li
XZxin zheng
xin zheng
Background Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction (AMI) after initial AMI remain poorly understood. Data on recurrent AMI in China is unknown. Methods Using the China Patient-centred Evaluative Assessment of Cardiac Events (PEACE)-Prospective AMI Study, we studied 3387 patients admitted to 53 hospitals for AMI and discharged alive. The association of recurrent AMI with 1-year mortality was evaluated using time-dependent Cox regression. Recurrent AMI events were classified as early (1–30 days), late (31–180 days), and very late (181–365 days). Their impacts on 1-year mortality were estimated by Kaplan-Meier methodology and compared by the log-rank test. Multivariable modelling was used to identify factors associated with recurrent AMI. Results The mean (SD) age was 60.7 (11.9) years and 783 (23.1%) were women. The observed 1-year recurrent AMI rate was 2.5% (95% CI 2.00 to 3.07) with 35.7% events occurring within the first 30 days. Recurrent AMI was associated with 1-year mortality with an adjusted HR of 25.42 (95% CI 15.27 to 42.34). Early recurrent AMI was associated with the highest 1-year mortality rate of 53.3% (log-rank p90 min/beats at initial admission, renal dysfunction, and not being prescribed any of guideline-based medications at discharge. Conclusions One-third of recurrent AMI events occurred early. Recurrent AMI is strongly associated with 1-year mortality, particularly if early. Heightened surveillance during this early period and improving prescription of recommended discharge medications may reduce recurrent AMI in China.

1 June 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Open access
PDF file
LMLin Mu
Lin Mu
JLJiamin Liu
Jiamin Liu
GZGuohai Zhou
Guohai Zhou
CWChaoqun Wu
Chaoqun Wu
BCBowang Chen
Bowang Chen
XZxin zheng
xin zheng
Background: China has seen a burgeoning epidemic of obesity in recent decades, but few studies reported nationally on obesity across socio-demographic subgroups. We sought to assess the prevalence and socio-demographic associations of obesity nationwide. Methods: We assessed the prevalence of overall obesity (body mass index ≥28 kg/m 2 ) and abdominal obesity (waist circumference ≥85/90 cm for women/men) among 2.7 million community-dwelling adults aged 35 to 75 years in the China PEACE Million Persons Project from 2014 to 2018 and quantified the socio-demographic associations of obesity using multivariable mixed models. Results: Age-standardized rates of overall and abdominal obesity were 14.4% (95% CI, 14.3%–14.4%) and 32.7% (32.6%–32.8%) in women and 16.0% (15.9%–16.1%) and 36.6% (36.5%–36.8%) in men. Obesity varied considerably across socio-demographic subgroups. Older women were at higher risk for obesity (eg, adjusted relative risk [95% CI] of women aged 65–75 versus 35–44 years: 1.29 [1.27–1.31] for overall obesity, 1.76 [1.74–1.77] for abdominal obesity) while older men were not. Higher education was associated with lower risk in women (eg, adjusted relative risk [95% CI] of those with college or university education versus below primary school: 0.47 [0.46–0.48] for overall obesity, 0.61 [0.60–0.62] for abdominal obesity) but higher risk in men (1.07 [1.05–1.10], 1.17 [1.16–1.19]). Conclusions: In China, over 1 in 7 individuals meet criteria for overall obesity, and 1 in 3 for abdominal obesity. Wide variation exists across socio-demographic subgroups. The associations of age and education with obesity are significant and differ by sex. Understanding obesity in contemporary China has broad domestic policy implications and provides a valuable international reference.

1 October 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
SMShiwani Mahajan
Shiwani Mahajan
DZDanwei Zhang
Danwei Zhang
SHSiyun He
Siyun He
YLYuan Lu
Yuan Lu
AGAakriti Gupta
Aakriti Gupta
JLJing Li
Jing Li
Background: Characterizing and assessing the prevalence, awareness, and treatment patterns of patients with isolated diastolic hypertension ( IDH ) can generate new knowledge and highlight opportunities to improve their care. Methods and Results: We used data from the China PEACE (Patient‐centered Evaluative Assessment of Cardiac Events) Million Persons Project, which screened 2 351 035 participants aged 35 to 75 years between 2014 and 2018. IDH was defined as systolic and diastolic blood pressure of <140 and ≥90 mm Hg; awareness as self‐reported diagnosis of hypertension; and treatment as current use of antihypertensive medications. Of the 2 310 184 participants included (mean age 55.7 years; 59.5% women); 73 279 (3.2%) had IDH , of whom 63 112 (86.1%) were untreated, and only 6512 (10.3%) of the untreated were aware of having hypertension. When compared with normotensives, participants who were 28 kg/m 2 , consumed alcohol, had diabetes mellitus, and prior cardiovascular events were more likely to have IDH (all P <0.01). Among those with IDH , higher likelihood of awareness was associated with increased age, women, college education, body mass index of >28 kg/m 2 , higher income, diabetes mellitus, prior cardiovascular events, and Central or Eastern region (all P <0.05). Most treated participants with IDH reported taking only 1 class of antihypertensive medication. Conclusions: IDH affects a substantial number of people in China, however, few are aware of having hypertension and most treated participants are poorly managed, which suggests the need to improve the diagnosis and treatment of people with IDH .

23 July 2024 in BMJ
Verified
Journal Article
Open access
PDF file
JSJiali Song
Jiali Song
XWXiuling Wang
Xiuling Wang
BWBin Wang
Bin Wang
YGYilan Ge
Yilan Ge
LBLei Bi
Lei Bi
XZxin zheng
xin zheng
Objective: To evaluate the effectiveness of a clinical decision support system (CDSS) in improving the use of guideline accordant antihypertensive treatment in primary care settings in China. Design: Pragmatic, open label, cluster randomised trial. Setting: 94 primary care practices in four urban regions of China between August 2019 and July 2022: Luoyang (central China), Jining (east China), and Shenzhen (south China, including two regions). Participants: 94 practices were randomised (46 to CDSS, 48 to usual care). 12 137 participants with hypertension who used up to two classes of antihypertensives and had a systolic blood pressure <180 mm Hg and diastolic blood pressure <110 mm Hg were included. Interventions: Primary care practices were randomised to use an electronic health record based CDSS, which recommended a specific guideline accordant regimen for initiation, titration, or switching of antihypertensive (the intervention), or to use the same electronic health record without CDSS and provide treatment as usual (control). Main outcome measures: The primary outcome was the proportion of hypertension related visits during which an appropriate (guideline accordant) treatment was provided. Secondary outcomes were the average reduction in systolic blood pressure and proportion of participants with controlled blood pressure (<140/90 mm Hg) at the last scheduled follow-up. Safety outcomes were patient reported antihypertensive treatment related events, including syncope, injurious fall, symptomatic hypotension or systolic blood pressure <90 mm Hg, and bradycardia. Results: 5755 participants with 23 113 visits in the intervention group and 6382 participants with 27 868 visits in the control group were included. Mean age was 61 (standard deviation 13) years and 42.5% were women. During a median 11.6 months of follow-up, the proportion of visits at which appropriate treatment was given was higher in the intervention group than in the control group (77.8% (17 975/23 113) v 62.2% (17 328/27 868); absolute difference 15.2 percentage points (95% confidence interval (CI) 10.7 to 19.8); P<0.001; odds ratio 2.17 (95% CI 1.75 to 2.69); P<0.001). Compared with participants in the control group, those in the intervention group had a 1.6 mm Hg (95% CI −2.7 to −0.5) greater reduction in systolic blood pressure (−1.5 mm Hg v 0.3 mm Hg; P=0.006) and a 4.4 percentage point (95% CI −0.7 to 9.5) improvement in blood pressure control rate (69.0% (3415/4952) v 64.6% (3778/5845); P=0.07). Patient reported antihypertensive treatment related adverse effects were rare in both groups. Conclusions: Use of a CDSS in primary care in China improved the provision of guideline accordant antihypertensive treatment and led to a modest reduction in blood pressure. The CDSS offers a promising approach to delivering better care for hypertension, both safely and efficiently. Trial registration: ClinicalTrials.gov NCT03636334 .

9 December 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
JSJiali Song
Jiali Song
YGYan Gao
Yan Gao
SHShuang Hu
Shuang Hu
EMEmanuela Medda
Emanuela Medda
GTGuigang Tang
Guigang Tang
XZxin zheng
xin zheng
Objective: Evidence of the effects of long-term fine particulate matter (PM 2.5 ) exposure on hypertension and blood pressure is limited for populations exposed to high levels of PM 2.5 . We aim to assess associations of long-term exposure to PM 2.5 with hypertension prevalence and blood pressure, and further explore the subpopulation differences and effect modification by participant characteristics in these associations in China. Methods: We analysed cross-sectional data from 883 827 participants aged 35–75 years in the China Patient-Centred Evaluative Assessment of Cardiac Events Million Persons Project. Data from the monitoring station were used to estimate the 1-year average concentration of PM 2.5 . The associations of PM 2.5 exposure with hypertension prevalence and blood pressure were investigated by generalised linear models, with PM 2.5 included as either linear or spline functions. Results: The 1-year PM 2.5 exposure of the study population ranged from 8.8 to 93.8 µg/m 3 (mean 49.2 µg/m 3 ). The adjusted OR of hypertension prevalence related to a 10 μg/m 3 increase in 1-year PM 2.5 exposure was 1.04 (95% CI, 1.02 to 1.05). Each 10 μg/m 3 increment in PM 2.5 exposure was associated with increases of 0.19 mm Hg (95% CI, 0.10 to 0.28) and 0.13 mm Hg (95% CI, 0.08 to 0.18) in systolic blood pressure and diastolic blood pressure, respectively. The concentration–response curves for hypertension prevalence and systolic blood pressure showed steeper slopes at higher PM 2.5 levels; while the curve for diastolic blood pressure was U-shaped. The elderly, men, non-current smokers and obese participants were more susceptible to the exposure of PM 2.5 . Conclusions: Long-term exposure to PM 2.5 is associated with higher blood pressure and increased risk of hypertension prevalence. The effects of PM 2.5 on hypertension prevalence become more pronounced at higher PM 2.5 levels. These findings emphasise the need to reduce air pollution, especially in areas with severe air pollution.

24 January 2020 in Heart
Verified
Journal Article
Closed access
PDF file
JLJiapeng Lu
Jiapeng Lu
LZLihua Zhang
Lihua Zhang
YLYuan Lu
Yuan Lu
MSMeng Su
Meng Su
XLXi Li
Xi Li
XZxin zheng
xin zheng
Objective We aimed to estimate the current use of secondary prevention drugs and identify its associated individual characteristics among those with established cardiovascular diseases (CVDs) in the communities of China. Methods We studied 2 613 035 participants aged 35–75 years from 8577 communities in 31 provinces in the China Patient-Centered Evaluative Assessment of Cardiac Events Million Persons Project, a government-funded public health programme conducted from 2014 to 2018. Participants self-reported their history of ischaemic heart disease (IHD) or ischaemic stroke (IS) and medication use in an interview. Multivariable mixed models with a logit link function and community-specific random intercepts were fitted to assess the associations of individual characteristics with the reported use of secondary prevention therapies. Results Among 2 613 035 participants, 2.9% (74 830) reported a history of IHD and/or IS, among whom the reported use rate either antiplatelet drugs or statins was 34.2% (31.5% antiplatelet drugs, 11.0% statins and 8.3% both). Among the 1 530 408 population subgroups, which were defined by all possible permutations of 16 individual characteristics, reported use of secondary prevention drugs varied substantially (8.4%–60.6%). In the multivariable analysis, younger people, women, current smokers, current drinkers, people without hypertension or diabetes and those with established CVD for more than 2 years were less likely to report taking antiplatelet drugs or statins. Conclusions The current use of secondary prevention drugs in China is suboptimal and varies substantially across population subgroups. Our study identifies target populations for scalable, tailored interventions to improve secondary prevention of CVD.